In 2025, many ATM authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspective and insightful view as authors.

Outstanding Authors (2026)

Yaniv S. Ovadia, Barzilai University Medical Center, Israel

Outstanding Author

Yaniv S. Ovadia

Dr. Yaniv S. Ovadia, RD, PhD, serves as a research dietitian and clinician in the Obstetrics and Gynecology Division at Barzilai University Medical Center, Ashkelon (BUMCA), Israel, where he also heads the Big Data Research Unit. His work centers on maternal nutrition, thyroid function during pregnancy, iodine status, and nutritional approaches to reduce complications such as preeclampsia. His recent projects include the development of an interventional pilot protocol examining early-harvest extra-virgin olive oil supplementation in women at high risk for preeclampsia.

ATM: What is fascinating about academic writing?

Dr. Ovadia: What continues to fascinate me is how academic writing transforms everyday clinical observations–such as patterns seen in high-risk prenatal clinics–into structured evidence that can inform practice and policy. It is especially rewarding when the process brings together clinicians, dietitians, biochemists, and basic scientists, as in our current preeclampsia-nutrition work. Writing becomes a bridge that turns small pilot findings into larger, well-funded initiatives. I am continually reminded that clear, modest communication of results invites new collaborations and helps secure the resources needed to move translational research forward.

ATM: Is it important for authors to disclose Conflict of Interest (COI)?

Dr. Ovadia: Yes, transparent disclosure of any potential COI is essential. In our olive oil protocol, for example, we openly noted the supply of EVOOEH by the Israeli Ministry of Agriculture’s Olive Division while emphasizing that the funder had no role in study design, analysis, or interpretation. A disclosed COI does not invalidate research when handled responsibly, but an undisclosed one can erode trust and limit future funding or collaborative opportunities. In my experience, full transparency actually strengthens credibility and encourages ethical partnerships across academia, hospitals, and industry.

ATM: Can you share tips on selecting the appropriate evidence for synthesis and analysis?

Dr. Ovadia: In preparing protocols like our recent EVOOEH pilot study, I have found it helpful to start with a focused question covering Patient or Population, Intervention, Comparison or Control, and Outcome (PICO) and then systematically prioritize peer-reviewed RCTs, meta-analyses, and high-quality cohort studies that match the target population (e.g., high-risk pregnancies). Tools such as SPIRIT guidelines help ensure transparency and completeness. Remaining humble about the limitations of existing data gaps often point to the need for new collaborative trials-and always document search strategies, inclusion/exclusion criteria, and risk-of-bias assessments can benefit authors. This disciplined approach can strengthen the manuscript, and hopefully highlights opportunities for future multicenter studies and funding applications.

(by Sasa Zhu, Brad Li)